CRA Attrition And The Pursuit Of Quality: The Benefits Of Comprehensive Oversight

Turnover in the pharmaceutical and biotech industry is ubiquitous, but it’s particularly high within certain specialties. Take Clinical Research Associates (CRAs), for example. According to a recent study published by BDO, “turnover levels for CRAs in the U.S. have been persistently high in recent years.” The report further noted that “turnover in CROs has hovered around 25% on average over the last five years, significantly higher than other industries.”

Unfortunately, the lack of access to qualified CRAs presents various challenges for clinical trials. Without experienced CRAs on staff, it can be difficult to ensure data quality and adhere to project deadlines. Nonetheless, it remains the responsibility of the trial sponsor to ensure patient safety and maintain the integrity of the clinical research.

While investing in CRA oversight was considered a luxury several years ago, it’s since increasingly become a necessity. Learn how the benefits of utilizing oversight CRAs can outweigh the costs and prevent trial disruptions.